Ovarian cancer is the most fatal gynecological cancer and the 8th most prevalent type of cancer in Iran. Chemotherapy regimen for the treatment of this type of cancer is mostly based on platinum agents and paclitaxel. The major problem during treatment with cisplatin is the appearance of acquired resistance in cancer cells in the first 6 months of therapy. Owing to inefficacy of second line regimens, it seems necessary to find out the molecular mechanisms of cisplatin resistance and find an efficient strategy against the resistant cancer cells. In this study, two ovarian cancer cell lines, A2780-sensitive and A2780CP (resistant to cisplatin) were evaluated. To acquire the protein expression profile, a culture of each line containing 1.5×107...
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resi...
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resi...
Abstract Background Significant miss‐expressed gene indicators contributing to cisplatin resistance ...
Cisplatin is an effective antitumor agent for the treatment of several solid tumors including human ...
Cisplatin [cis-diamminedichloroplatinum (II)] is one of the most potent and highly effective chemoth...
Cisplatin [cis-diamminedichloroplatinum (II)] is one of the most potent and highly effective chemoth...
Since drug resistance is a complex and multifactorial event involving activation/repression of multi...
Background: The management of ovarian cancer remains a challenge. Because of the lack of early sympt...
Cisplatin along with other platinum based drugs are some of the most widely used chemotherapeutic ag...
Studies were undertaken to investigate acquired resistance to cisplatin in human ovarian cancer cell...
Ovarian cancer is one of the leading causes of mortality by gynecological cancer. Despite good respo...
Ovarian cancer is one of the leading causes of mortality by gynecological cancer. Despite good respo...
The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and model...
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resi...
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resi...
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resi...
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resi...
Abstract Background Significant miss‐expressed gene indicators contributing to cisplatin resistance ...
Cisplatin is an effective antitumor agent for the treatment of several solid tumors including human ...
Cisplatin [cis-diamminedichloroplatinum (II)] is one of the most potent and highly effective chemoth...
Cisplatin [cis-diamminedichloroplatinum (II)] is one of the most potent and highly effective chemoth...
Since drug resistance is a complex and multifactorial event involving activation/repression of multi...
Background: The management of ovarian cancer remains a challenge. Because of the lack of early sympt...
Cisplatin along with other platinum based drugs are some of the most widely used chemotherapeutic ag...
Studies were undertaken to investigate acquired resistance to cisplatin in human ovarian cancer cell...
Ovarian cancer is one of the leading causes of mortality by gynecological cancer. Despite good respo...
Ovarian cancer is one of the leading causes of mortality by gynecological cancer. Despite good respo...
The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and model...
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resi...
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resi...
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resi...
The major obstacle in the clinical use of the antitumor drug cisplatin is inherent and acquired resi...
Abstract Background Significant miss‐expressed gene indicators contributing to cisplatin resistance ...